Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs

Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs

At present there are no drugs for the treatment of chronic liver fibrosis that have been approved by the Food and Drug Administration of the United States. Telmisartan, a small-molecule antihypertensive drug, displays antifibrotic activity, but its clinical use is limited because it causes systemic...

Full description

Bibliographic Details
Main Authors: Golder, Matthew R (Author), Liu, Jenny (Author), Andersen, Jannik N. (Author), Shipitsin, Michail V. (Author), Vohidov, Farrukh (Author), Nguyen, Hung V.-T (Author), Ehrlich, Deborah C. (Author), Huh, Sung Jin (Author), Vangamudi, Bhavatarini (Author), Economides, Kyriakos D. (Author), Neenan, Allison M. (Author), Ackley, James C. (Author), Baddour, Joelle (Author), Paramasivan, Sattanathan (Author), Brady, Samantha W. (Author), Held, Eric J. (Author), Reiter, Lawrence A. (Author), Saucier-Sawyer, Jennifer K. (Author), Kopesky, Paul W. (Author), Chickering, Donald E. (Author), Blume-Jensen, Peter (Author), Johnson, Jeremiah A. (Author)
Other Authors: Massachusetts Institute of Technology. Department of Chemistry (Contributor)
Format: Article
Language:English
Published: Springer Nature, 2020-01-22T18:39:56Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items